

Remarks

In the February 24, 2009 Office Action, the Examiner required applicants to elect one single species from the following species:

Methotrexate;  
Infliximab;  
Etanercept;  
Leflunomide;  
Sulfasalazine;  
Azathioprine;  
Cyclosporine;  
Hydroxychloroquine; and  
Penicillamine.

In response, applicants elect, without traverse, methotrexate as the species in the event no generic claim is finally deemed allowable.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone her at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 13-2755.

Respectfully submitted,

By Maria V. Marucci  
Maria V. Marucci  
Reg. No. 59,895  
Attorney for Applicants

MERCK & CO., INC.  
P.O. Box 2000, RY 60-30  
Rahway, NJ 07065-0900  
(732) 594-1637

Date: March 19, 2009